GlaxoSmithKline Aligns With Cellzome | Chemical & Engineering News
Volume 86 Issue 37 | p. 19 | Concentrates
Issue Date: September 15, 2008

GlaxoSmithKline Aligns With Cellzome

Department: Business

GlaxoSmithKline has teamed up with the privately owned drug discovery firm Cellzome to find and develop selective kinase inhibitors to treat inflammatory diseases such as multiple sclerosis and arthritis. GSK will pay about $25 million for an exclusive option to license small molecules that act against four identified targets, as well as against three new targets to be jointly discovered by the partners. Cellzome's technology uses native kinases isolated from human cells and tissues. The company says that approach enables screening of compounds in a physiological setting, thus providing a better idea of how drug candidates will act in humans.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment